ProfileGDS5678 / 1442428_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 42% 41% 41% 40% 42% 41% 44% 40% 42% 42% 41% 42% 41% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.015242
GSM967853U87-EV human glioblastoma xenograft - Control 22.942641
GSM967854U87-EV human glioblastoma xenograft - Control 32.9503341
GSM967855U87-EV human glioblastoma xenograft - Control 42.8545140
GSM967856U87-EV human glioblastoma xenograft - Control 52.9196242
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.047541
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.079144
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9197840
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.936742
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.949542
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9358441
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9396542
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.955941
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9478141